tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2016-3-5-10tumors-254Research ArticleФУНДАМЕНТАЛЬНАЯ ОНКОЛОГИЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАFUNDAMENTAL ONCOLOGY AND EXPERIMENTAL MEDICINEМноголикая биология рака молочной железы: поиски адекватного леченияDiverse biology of breast cancer: search for adequate treatmentСЕМИГЛАЗОВВ. Ф.SEMIGLAZOVV. F.

заведующий научным отделом опухолей репродуктивной системы; член-корр. РАН, профессор

 

professor, head of Reproductive system tumors research department

ssemiglazov@mail.ruФГБУ НИИ онкологии им. Н. Н. Петрова МЗ РФРоссияFGBU N.N.Petrov Oncological Research InstitutionRussian Federation20161410201603510Copyright © СЕМИГЛАЗОВ В.Ф., 20162016СЕМИГЛАЗОВ В.Ф.SEMIGLAZOV V.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/254

В статье представлены результаты последних исследований механизмов резистентности к эндокринотерапии ER+ люминальных опухолей и анти-HER2 терапии HER2 – позитивных опухолей, а также информация о существовании шести молекулярно-генетических подтипов среди трижды негативного рака молочной железы (РМЖ). Делается вывод о том, что более точная молекулярно-генетическая характеристика клинических (ИГХ) подтипов РМЖ улучшит планирование адекватного лечения.

The article describes the results of the latest studies focused on the mechanisms of resistance for endocrine therapy of ER+ luminal tumors and anti-HER2 therapy of HER2-positive tumors. Also the author gives an information about six molecular-genetic subtypes among triple-negative breast cancer (BC) concluding that more precise molecular-genetic tests of clinical subtypes (IHC) would improve planning of adequate treatment.

патологические подтипы рака молочной железысистемное лечениеpathological subtypes of breast cancersystematic treatmentReferencesВ.Ф. Семиглазов, В. В. Семиглазов, П. В. Криворотько, Р. М. Палтуев, Г. А. Дашян, Т. Ю. Семиглазова, А. А. Бессонов, К. С. Николаев. Руководство по лечению раннего рака молочной железы – СПб.: Книга по Требованию, 2016. – 154 с.В.Ф. Семиглазов, В. В. Семиглазов, П. В. Криворотько, Р. М. Палтуев, Г. А. Дашян, Т. Ю. Семиглазова, А. А. Бессонов, К. С. Николаев. Руководство по лечению раннего рака молочной железы – СПб.: Книга по Требованию, 2016. – 154 с.В.Ф. Семиглазов, В. В. Семиглазов. Рак молочной железы: биология, местное и системное лечение. – Москва: СИМК, 2014. – 352 с.В.Ф. Семиглазов, В. В. Семиглазов. Рак молочной железы: биология, местное и системное лечение. – Москва: СИМК, 2014. – 352 с.Early Breast Cancer Trialists Collaborative Group. Comparison between different polychemotherapy regiments for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials. Lancet, 2012. Vol. 379, pp. 432– 444.Early Breast Cancer Trialists Collaborative Group. Comparison between different polychemotherapy regiments for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials. Lancet, 2012. Vol. 379, pp. 432– 444.Eiermann W., Paepke S., Appfelstaedt J. et al. Preoperative treatment of postmenopausal breast cancer with letrozole: a randomized double blind multicenter study. Ann Oncol, 2001. Vol. 12, pp. 1527–1532/.Eiermann W., Paepke S., Appfelstaedt J. et al. Preoperative treatment of postmenopausal breast cancer with letrozole: a randomized double blind multicenter study. Ann Oncol, 2001. Vol. 12, pp. 1527–1532/.Semiglazov V. F., Semiglazov V. V., Ivanov V. et al. The relative efficacy of neoadjuvant endocrine therapy vs postmenopausal women with ER-positive breast cancer// J. Clin. Oncol. – 2004. – Vol. 22. – P. 519.Semiglazov V. F., Semiglazov V. V., Ivanov V. et al. The relative efficacy of neoadjuvant endocrine therapy vs postmenopausal women with ER-positive breast cancer// J. Clin. Oncol. – 2004. – Vol. 22. – P. 519.Semiglazov V. F., Kletsel A., Semiglazov V. V. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0): Program and abstracts of the 41st Annual Meeting of the ASCO (abstr. 530). // J clinOncol / – 2005. – Vol. 23.Semiglazov V. F., Kletsel A., Semiglazov V. V. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0): Program and abstracts of the 41st Annual Meeting of the ASCO (abstr. 530). // J clinOncol / – 2005. – Vol. 23.Semiglazov V. F., Semiglazov V. V., Dashyan G. et al. Phase II randomized trial of primary endocrine therapy chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. //. Cancer, 2007. Vol. 110 (2), pp. 244–254Semiglazov V. F., Semiglazov V. V., Dashyan G. et al. Phase II randomized trial of primary endocrine therapy chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. //. Cancer, 2007. Vol. 110 (2), pp. 244–254Semiglazov V. F., Semiglazov V. V., Neoadjuvant systemic therapy in breast cancer. Charter I. In book. Neoadjuvant chemotherapy – current appeications in clinical practice. Ed. Oliver F. Bathe. In Tech. Croatia. – 2012. www.intechopen. com. P. 1–22.Semiglazov V. F., Semiglazov V. V., Neoadjuvant systemic therapy in breast cancer. Charter I. In book. Neoadjuvant chemotherapy – current appeications in clinical practice. Ed. Oliver F. Bathe. In Tech. Croatia. – 2012. www.intechopen. com. P. 1–22.Colleoni M, Gelber S et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: International Breast Cancer Study Group trial 13–93. J Clin Oncol, 2006. Vol. 24, pp. 1332–1341.Colleoni M, Gelber S et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: International Breast Cancer Study Group trial 13–93. J Clin Oncol, 2006. Vol. 24, pp. 1332–1341.ColleoniM., Anders C., Debate: The biology of breast cancer in young women is unique. The Oncolog 2013 – vol. IS-pp. 344–345.ColleoniM., Anders C., Debate: The biology of breast cancer in young women is unique. The Oncolog 2013 – vol. IS-pp. 344–345.Sun Z., Prat A., Chang M., Gelber., Perou C. Chemotherapy benefit for «ER-positive» breast cancer and contamination of non-luminal subtypes – waiting for TAILORx and Rx PONDER. Ann. Onclo. 2015- vol. 26. P. 70–74.Sun Z., Prat A., Chang M., Gelber., Perou C. Chemotherapy benefit for «ER-positive» breast cancer and contamination of non-luminal subtypes – waiting for TAILORx and Rx PONDER. Ann. Onclo. 2015- vol. 26. P. 70–74.Baselga J., Semiglazov V., van Dam P. et al. Phase II randomized study of neoadjuvant evrolimus plus letrozole compared with placebo plus letrozolein patients with estrogen receptor-positive breast cancer.// J. Clin Oncol. – 2009. – Vol. 27 (6). – P. 2630–2637.Baselga J., Semiglazov V., van Dam P. et al. Phase II randomized study of neoadjuvant evrolimus plus letrozole compared with placebo plus letrozolein patients with estrogen receptor-positive breast cancer.// J. Clin Oncol. – 2009. – Vol. 27 (6). – P. 2630–2637.Regan M. Predicting benefit of endocrine therapy. The BREAST. – 2015. – vol. 20. Suppl.1. abstr. PG 11.03.Regan M. Predicting benefit of endocrine therapy. The BREAST. – 2015. – vol. 20. Suppl.1. abstr. PG 11.03.Burstein H. Endocrine therapy for postmenopausal patient: type and duration. The BREAST. – 2015. – vol.20. suppl.1. – abstr. PG 11.02.Burstein H. Endocrine therapy for postmenopausal patient: type and duration. The BREAST. – 2015. – vol.20. suppl.1. – abstr. PG 11.02.Cristofanilli M., Tuner N., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA‑3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.Cristofanilli M., Tuner N., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA‑3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.Turnbull A ., Aithur L., Renshaw L., Larionov A., Dowsett M., Dixon M. Accurate prediction and validation of response to endocrine therapy in breast cancer. J. Clin Oncol., 2015-vol. 33. – n20. – pp.2270–2278.Turnbull A ., Aithur L., Renshaw L., Larionov A., Dowsett M., Dixon M. Accurate prediction and validation of response to endocrine therapy in breast cancer. J. Clin Oncol., 2015-vol. 33. – n20. – pp.2270–2278.Ellis M. J., Suman V. J., Hoog J. et al. Randomized phase IIneoadjuvant comparison between letrozole, anastrozole andexemestance for postmenopausal women with estrogenreceptor- rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAMSO-basedintrinsic subtype-ACOSOG Z1013.// J Clin Oncol. – 2011. – Vol. 29. – P. 2342–2349.Ellis M. J., Suman V. J., Hoog J. et al. Randomized phase IIneoadjuvant comparison between letrozole, anastrozole andexemestance for postmenopausal women with estrogenreceptor- rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAMSO-basedintrinsic subtype-ACOSOG Z1013.// J Clin Oncol. – 2011. – Vol. 29. – P. 2342–2349.Gianni L., Pienkowski T., Roman L. et al. Addition of pertuzumab (P) to trastuzumab(H) –based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: result of a randomized phase II study (NEOSPHERE).// The Breast. –2011. – Vol. 20 (suppl 1.) – P. 573.Gianni L., Pienkowski T., Roman L. et al. Addition of pertuzumab (P) to trastuzumab(H) –based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: result of a randomized phase II study (NEOSPHERE).// The Breast. –2011. – Vol. 20 (suppl 1.) – P. 573.Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab, followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HERpositive, locally advanced breast cancer (theNOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort.// The Lancet. – 2010. – vol 375. – P. 377–384, ISSN0140–6736.Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab, followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HERpositive, locally advanced breast cancer (theNOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort.// The Lancet. – 2010. – vol 375. – P. 377–384, ISSN0140–6736.Piccart-Gebhart M.J., Holmes A.P., Baselga J. et al. Firast results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol, 2014. Vol. 32 (Suppl. 5s); abstr. LBA4.Piccart-Gebhart M.J., Holmes A.P., Baselga J. et al. Firast results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol, 2014. Vol. 32 (Suppl. 5s); abstr. LBA4.Loi S., Savas P., Looking deep Into the Heterogenity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer:Can We Understand It Better? J Clim Oncol. 2016. – vol.34. – N6. – pp. 521–523.Loi S., Savas P., Looking deep Into the Heterogenity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer:Can We Understand It Better? J Clim Oncol. 2016. – vol.34. – N6. – pp. 521–523.Loibl S., von Minckwitz G., Schneeweiss A., et al. PIK3C3 Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor (HER2) Therapy in Primary HER2-Overexpressing breast Cancer. J. Clin Oncol.; 2014. – vol. 32. – pp. 3212–3220.Loibl S., von Minckwitz G., Schneeweiss A., et al. PIK3C3 Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor (HER2) Therapy in Primary HER2-Overexpressing breast Cancer. J. Clin Oncol.; 2014. – vol. 32. – pp. 3212–3220.Henry L., Schott A., Hayes D. Assessment of PIK3CA Mutations in Human Epidermal Growth Factor Receptor 2- Positive Breast Cancer: Clinical Validity but Not Utility. J Clin Oncol., 2014. – vol.32. – pp.3207–3209.Henry L., Schott A., Hayes D. Assessment of PIK3CA Mutations in Human Epidermal Growth Factor Receptor 2- Positive Breast Cancer: Clinical Validity but Not Utility. J Clin Oncol., 2014. – vol.32. – pp.3207–3209.Loi S. Michiels S. Salgado R. et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial Ann Oncol. – 2014. – 15: e58-e68.Loi S. Michiels S. Salgado R. et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial Ann Oncol. – 2014. – 15: e58-e68.Bianchini G. Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. –2014. – 15: e58-e68.Bianchini G. Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. –2014. – 15: e58-e68.Carey L., Perou C., Winer E., Huds G., Molecular heterogeneity and response to neoadjuvant HER2 targeting (paclitaxel plus trastuzumab with or without lapatinib). J Clin omcol. 2016. – vol 34. – № 6 pp 542–549.Carey L., Perou C., Winer E., Huds G., Molecular heterogeneity and response to neoadjuvant HER2 targeting (paclitaxel plus trastuzumab with or without lapatinib). J Clin omcol. 2016. – vol 34. – № 6 pp 542–549.Iglesia M.D. Vincent B.G. Parker J.S. et al: Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. – 2014. – 20:3818–3829.Iglesia M.D. Vincent B.G. Parker J.S. et al: Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. – 2014. – 20:3818–3829.Fan C. Prat A. Parker JS. et al: Building prognostic models for breast cancer patients using clinical variables and hundreds ofgene expression signatures. BMC Med Genomics. – 2011. – 4:3.Fan C. Prat A. Parker JS. et al: Building prognostic models for breast cancer patients using clinical variables and hundreds ofgene expression signatures. BMC Med Genomics. – 2011. – 4:3.Parker J.S. Mullins M. Cheang M.C. et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. – 2009. – 27:1160–1167.Parker J.S. Mullins M. Cheang M.C. et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. – 2009. – 27:1160–1167.Baselga J. Bradbry I. Eidtmann H. et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomized, open-label, multicentre phase 3 trial. Lancet. – 2012. – 379:633–640.Baselga J. Bradbry I. Eidtmann H. et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomized, open-label, multicentre phase 3 trial. Lancet. – 2012. – 379:633–640.Gianni L. Pienkowski T. Im Y.H. et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or early HER2-positive breast cancer (NeoSphere): A randomised multicentre open-labe; phase 2 trial. Lancet Oncol. – 2012. – 13:25–32.Gianni L. Pienkowski T. Im Y.H. et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or early HER2-positive breast cancer (NeoSphere): A randomised multicentre open-labe; phase 2 trial. Lancet Oncol. – 2012. – 13:25–32.Blackwell K. Mechanisms of Trastuzumab Resistance in HER2+ Breast Cancer. ASCO Annual Meeting 16. ASCO Educational Book. – 2016. – pp. 16–28.Blackwell K. Mechanisms of Trastuzumab Resistance in HER2+ Breast Cancer. ASCO Annual Meeting 16. ASCO Educational Book. – 2016. – pp. 16–28.Anders C., Abramson V., Tan T., Dent R. The evolution of triple-negative breast cancer from biology to novel therapeutics. ASCO Educational Book., 2016. – p 34–42.Anders C., Abramson V., Tan T., Dent R. The evolution of triple-negative breast cancer from biology to novel therapeutics. ASCO Educational Book., 2016. – p 34–42.

The authors declare that there are no conflicts of interest present.